TY - JOUR
TI - Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
AU - Liapis, K.
AU - Papadopoulos, V.
AU - Vrachiolias, G.
AU - Galanopoulos, A.G.
AU - Papoutselis, M.
AU - Papageorgiou, S.G.
AU - Diamantopoulos, P.T.
AU - Pappa, V.
AU - Viniou, N.-A.
AU - Kourakli, A.
AU - Τsokanas, D.
AU - Vassilakopoulos, T.P.
AU - Hatzimichael, E.
AU - Bouronikou, E.
AU - Ximeri, M.
AU - Pontikoglou, C.
AU - Megalakaki, A.
AU - Zikos, P.
AU - Panayiotidis, P.
AU - Dimou, M.
AU - Karakatsanis, S.
AU - Papaioannou, M.
AU - Vardi, A.
AU - Kontopidou, F.
AU - Harchalakis, N.
AU - Adamopoulos, I.
AU - Symeonidis, A.
AU - Kotsianidis, I.
JO - Blood cancer journal
PY - 2021
VL - 11
TODO - 2
SP - null
PB - Springer Nature BV
SN - null
TODO - 10.1038/s41408-021-00424-4
TODO - azacitidine;  beta 2 microglobulin;  antineoplastic antimetabolite;  azacitidine, aged;  assessment of humans;  blast cell;  blood transfusion;  bone marrow cell;  cancer prognosis;  cancer specific survival;  cytogenetics;  drug efficacy;  Endothelial Activation and Stress Index;  estimated glomerular filtration rate;  female;  high risk patient;  human;  intermediate risk patient;  International Prognostic Scoring System;  Letter;  low risk patient;  major clinical study;  male;  myelodysplastic syndrome;  overall survival;  risk factor;  adult;  follow up;  middle aged;  myelodysplastic syndrome;  prognosis;  survival analysis;  very elderly, Adult;  Aged;  Aged, 80 and over;  Antimetabolites, Antineoplastic;  Azacitidine;  Female;  Follow-Up Studies;  Humans;  Male;  Middle Aged;  Myelodysplastic Syndromes;  Prognosis;  Risk Factors;  Survival Analysis
TODO - null
ER -